

REFERENCES

- 1: Stefani M and Dobson CM. (2003) Protein aggregation and aggregate toxicity: new insights into protein folding, misfolding diseases and biological evolution. *J Mol Med.* **81**(11):678-99.
- 2: Stefani M. (2004) Protein misfolding and aggregation: new examples in medicine and biology of the dark side of the protein world. *Biochim Biophys Acta.* **1739**(1):5-25.
- 3: Chiti F and Dobson CM. (2006) Protein misfolding, functional amyloid, and human disease. *Annu Rev Biochem.* **75**:333-66.
- 4: Guijarro JI, Sunde M, Jones JA, Campbell ID and Dobson CM. (1998) Amyloid fibril formation by an SH3 domain. *Proc Natl Acad Sci U S A.* **95**(8):4224-8.
- 5: Chiti F, Bucciantini M, Capanni C, Taddei N, Dobson CM and Stefani M. (2001) Solution conditions can promote formation of either amyloid protofilaments or mature fibrils from the HypF N-terminal domain. *Protein Sci.* **10**(12):2541-7.
- 6: Uversky VN and Fink AL. (2004) Conformational constraints for amyloid fibrillation: the importance of being unfolded. *Biochim Biophys Acta.* **1698**(2):131-53.
- 7: Nilsson MR. (2004) Techniques to study amyloid fibril formation in vitro. *Methods.* **34**(1):151-60.
- 8: Serpell LC. (2000) Alzheimer's amyloid fibrils: structure and assembly. *Biochim Biophys Acta.* **1502**(1):16-30.
- 9: LeVine H 3rd. (1993) Thioflavine T interaction with synthetic Alzheimer's disease beta-amyloid peptides: detection of amyloid aggregation in solution. *Protein Sci.* **2**(3):404-10.
- 10: Munishkina LA and Fink AL. (2007) Fluorescence as a method to reveal structures and membrane-interactions of amyloidogenic proteins. *Biochim Biophys Acta.* **1768**(8):1862-85.
- 11: Sunde M, Serpell LC, Bartlam M, Fraser PE, Pepys MB and Blake CC. (1997) Common core structure of amyloid fibrils by synchrotron X-ray diffraction. *J Mol Biol.* **273**(3):729-39.
- 12: Serpell LC, Sunde M, Benson MD, Tennent GA, Pepys MB and Fraser PE. (2000) The protofilament substructure of amyloid fibrils. *J Mol Biol.* **28**;300(5):1033-9.
- 13: Makin OS and Serpell LC. (2005) Structures for amyloid fibrils. *FEBS J.* **272**(23):5950-61.
- 14: Wetzel R. (2002) Ideas of order for amyloid fibril structure. *Structure.* **10**(8):1031-6
- 15: Kourie JI, Henry CL and Farrelly P. (2001) Diversity of amyloid beta protein fragment [1-40]-formed channels. *Cell Mol Neurobiol.* **21**(3):255-84.
- 16: Chamberlain AK, MacPhee CE, Zurdo J, Morozova-Roche LA, Hill HA, Dobson CM and Davis JJ. (2000) Ultrastructural organization of amyloid fibrils by atomic force microscopy. *Biophys J.* **79**(6):3282-93.
- 17: Laurine E, Grégoire C, Fändrich M, Engemann S, Marchal S. et al. (2003) Lithostathine quadruple-helical filaments form proteinase K-resistant deposits in Creutzfeldt-Jakob disease. *J Biol Chem.* **278**(51):51770-8.
- 18: Harper JD, Lieber CM and Lansbury PT Jr. (1997) Atomic force microscopic imaging of seeded fibril formation and fibril branching by the Alzheimer's disease amyloid-beta protein. *Chem Biol.* **4**(12):951-9.
- 19: Lashuel HA, Hartley D, Petre BM, Walz T and Lansbury PT Jr. (2002) Neurodegenerative disease: amyloid pores from pathogenic mutations. *Nature.* **418**(6895):291.
- 20: Quintas A, Vaz DC, Cardoso I, Saraiva MJ and Brito RM. (2001) Tetramer dissociation and monomer partial unfolding precedes protofibril formation in amyloidogenic transthyretin variants. *J Biol Chem.* **276**(29):27207-13.

- 21:** Kayed R, Head E, Thompson JL, McIntire TM, Milton SC. et al. (2003) Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. *Science*. **300**(5618): 486-9.
- 22:** Hardy J and Selkoe DJ. (2002) The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. *Science*. **297**(5580):353-6.
- 23:** Lashuel HA and Lansbury PT Jr. (2006) Are amyloid diseases caused by protein aggregates that mimic bacterial pore-forming toxins? *Q Rev Biophys*. **39**(2):167-201.
- 24:** Lue LF, Kuo YM, Roher AE, Brachova L, Shen Y. et al. (1999) Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease. *Am J Pathol*. **155**(3): 853-62.
- 25:** Haass C and Selkoe DJ. (2007) Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. *Nat Rev Mol Cell Biol*. **8**(2):101-12.
- 26:** Carulla N, Caddy GL, Hall DR, Zurdo J, Gairí M, Feliz M, Giralt E, Robinson CV and Dobson CM. (2005) Molecular recycling within amyloid fibrils. *Nature*. **436**(7050):554-8.
- 27:** Novitskaya V, Bocharova OV, Bronstein I and Baskakov IV. (2006) Amyloid fibrils of mammalian prion protein are highly toxic to cultured cells and primary neurons. *J Biol Chem*. **281**(19):13828-36.
- 28:** Gharibyan AL, Zamotin V, Yanamandra K, Moskaleva OS, Margulis BA, Kostanyan IA and Morozova-Roche LA. (2007) Lysozyme amyloid oligomers and fibrils induce cellular death via different apoptotic/necrotic pathways. *J Mol Biol*. **365**(5):1337-49.
- 29:** Petkova AT, Leapman RD, Guo Z, Yau WM, Mattson MP and Tycko R. (2005) Self-propagating, molecular-level polymorphism in Alzheimer's beta-amyloid fibrils. *Science*. **307**(5707):262-5.
- 30:** Kawahara M, Kuroda Y, Arispe N and Rojas E. (2000) Alzheimer's beta-amyloid, human islet amylin, and prion protein fragment evoke intracellular free calcium elevations by a common mechanism in a hypothalamic GnRH neuronal cell line. *J Biol Chem*. **275**(19):14077-83.
- 31:** Bucciantini M, Giannoni E, Chiti F, Baroni F, Formigli L. et al. (2002) Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases. *Nature*. **416**(6880): 507-11.
- 32:** Hirakura Y and Kagan BL. (2001) Pore formation by beta-2-microglobulin: a mechanism for the pathogenesis of dialysis associated amyloidosis. *Amyloid*. **8**(2):94-100.
- 33:** Volles MJ and Lansbury PT Jr (2002) Vesicle permeabilization by protofibrillar alpha-synuclein is sensitive to Parkinson's disease-linked mutations and occurs by a pore-like mechanism. *Biochemistry*. **41**(14):4595-602.
- 34:** Lin H, Bhatia R and Lal R. (2001) Amyloid beta protein forms ion channels: implications for Alzheimer's disease pathophysiology. *FASEB J*. **15**(13):2433-44.
- 35:** Ding F, Dokholyan NV, Buldyrev SV, Stanley HE and Shakhnovich EI. (2002) Molecular dynamics simulation of the SH3 domain aggregation suggests a generic amyloidogenesis mechanism. *J Mol Biol*. **324**(4):851-7.
- 36:** Zhu YJ, Lin H and Lal R. (2000) Fresh and nonfibrillar amyloid beta protein(1-40) induces rapid cellular degeneration in aged human fibroblasts: evidence for AbetaP-channel-mediated cellular toxicity. *FASEB J*. **14**(9):1244-54.
- 37:** Kourie JI and Shorthouse AA. (2000) Properties of cytotoxic peptide-formed ion channels. *Am J Physiol Cell Physiol*. **278**(6):C1063-87.
- 38:** Milhavet O and Lehmann S. (2002) Oxidative stress and the prion protein in transmissible spongiform encephalopathies. *Brain Res Brain Res Rev*. **38**(3):328-39.

- 39:** Zhang L, Xing GQ, Barker JL, Chang Y, Maric D, Ma W, Li BS and Rubinow DR. (2001) Alpha-lipoic acid protects rat cortical neurons against cell death induced by amyloid and hydrogen peroxide through the Akt signalling pathway. *Neurosci Lett.* **312**(3):125-8.
- 40:** Mattson MP. (1999) Impairment of membrane transport and signal transduction systems by amyloidogenic proteins. *Methods Enzymol.* **309**:733-46.
- 41:** Squier TC. (2001) Oxidative stress and protein aggregation during biological aging. *Exp Gerontol.* **36**(9):1539-50.
- 42:** Butterfield DA, Drake J, Pocernich C and Castegna A. (2001) Evidence of oxidative damage in Alzheimer's disease brain: central role for amyloid beta-peptide. *Trends Mol Med.* **7**(12): 548-54.
- 43:** Varadarajan S, Yatin S, Aksenova M and Butterfield DA. (2000) Review: Alzheimer's amyloid beta-peptide-associated free radical oxidative stress and neurotoxicity. *J Struct Biol.* **130**(2-3): 184-208.
- 44:** Kourie JI and Henry CL. (2002) Ion channel formation and membrane-linked pathologies of misfolded hydrophobic proteins: the role of dangerous unchaperoned molecules. *Clin Exp Pharmacol Physiol.* **29**(9):741-53.
- 45:** Arispe N, Rojas E and Pollard HB. (1993) Alzheimer disease amyloid beta protein forms calcium channels in bilayer membranes: blockade by tromethamine and aluminum. *Proc Natl Acad Sci U S A.* **90**(2):567-71.
- 46:** Kourie JI. (2001a) Mechanisms of amyloid beta protein-induced modification in ion transport systems: implications for neurodegenerative diseases. *Cell Mol Neurobiol.* **21**(3):173-213.
- 47:** Tagliavini F, Lievens PM, Tranchant C, Warter JM, Mohr M. et al. (2001) A 7-kDa prion protein (PrP) fragment, an integral component of the PrP region required for infectivity, is the major amyloid protein in Gerstmann-Sträussler-Scheinker disease A117V. *J Biol Chem.* **276**(8): 6009-15.
- 48:** Gasset M, Baldwin MA, Fletterick RJ and Prusiner SB. (1993) Perturbation of the secondary structure of the scrapie prion protein under conditions that alter infectivity. *Proc Natl Acad Sci U S A.* **90**(1):1-5.
- 49:** Kourie JI. (2001b) Mechanisms of prion-induced modifications in membrane transport properties: implications for signal transduction and neurotoxicity. *Chem Biol Interact.* **138**(1): 1-26.
- 50:** Alarcón JM, Brito JA, Hermosilla T, Atwater I, Mears D and Rojas E. (2006) Ion channel formation by Alzheimer's disease amyloid beta-peptide (Abeta40) in unilamellar liposomes is determined by anionic phospholipids. *Peptides.* **27**(1):95-104.
- 51:** Volles MJ, Lee SJ, Rochet JC, Shilerman MD, Ding TT, Kessler JC and Lansbury PT Jr. (2001) Vesicle permeabilization by protofibrillar alpha-synuclein: implications for the pathogenesis and treatment of Parkinson's disease. *Biochemistry.* **40**(26):7812-9.
- 52:** Diociaiuti M, Polzi LZ, Valvo L, Malchiodi-Albedi F, Bombelli C and Gaudiano MC. (2006) Calcitonin forms oligomeric pore-like structures in lipid membranes. *Biophys J.* **91**(6):2275-81.
- 53:** Sparr E, Engel MF, Sakharov DV, Sprong M, Jacobs J, de Kruijff B, Höppener JW and Killian JA. (2004) Islet amyloid polypeptide-induced membrane leakage involves uptake of lipids by forming amyloid fibers. *FEBS Lett.* **577**(1-2):117-20.
- 54:** Zhao H, Tuominen EK and Kinnunen PK. (2004) Formation of amyloid fibers triggered by phosphatidylserine-containing membranes. *Biochemistry.* **43**(32):10302-7.
- 55:** Mason RP, Shoemaker WJ, Shajenko L, Chambers TE and Herbette LG. (1992) Evidence for changes in the Alzheimer's disease brain cortical membrane structure mediated by cholesterol. *Neurobiol Aging.* **13**(3):413-9.

- 56:** Arispe N and Doh M. (2002) Plasma membrane cholesterol controls the cytotoxicity of Alzheimer's disease AbetaP (1-40) and (1-42) peptides. *FASEB J.* **16**(12):1526-36.
- 57:** Mirzabekov TA, Lin MC and Kagan BL. (1996) Pore formation by the cytotoxic islet amyloid peptide amylin. *J Biol Chem.* **271**(4):1988-92.
- 58:** Jayasinghe SA and Langen R. (2007) Membrane interaction of islet amyloid polypeptide. *Biochim Biophys Acta.* **1768**(8):2002-9.
- 59:** Ran S and Thorpe PE. (2002) Phosphatidylserine is a marker of tumor vasculature and a potential target for cancer imaging and therapy. *Int J Radiat Oncol Biol Phys.* **54**(5):1479-84.
- 60:** Zhu M, Souillac PO, Ionescu-Zanetti C, Carter SA and Fink AL. (2002) Surface-catalyzed amyloid fibril formation. *J Biol Chem.* **277**(52):50914-22.
- 61:** American Diabetes Association. (2006) Diagnosis and classification of diabetes mellitus. *Diabetes Care* **29**(suppl.1): S43:48.
- 62:** DeFronzo RA. (1988) The triumvirate: beta-cell, muscle, liver. A collusion responsible for NIDDM. *Diabetes.* **37**(6):667-87.
- 63:** Ferrannini E, and Mari A. (2004) Beta-cell function and its relation to insulin action in humans: a critical appraisal. *Diabetologia* **47:943-56.**
- 64:** Levy J, Atkinson AB, Bell PM, et al. (1998) Beta-cell deterioration determines the onset and rate of progression of secondary dietary failure in type 2 diabetes mellitus: the 10-year follow-up of the Belfast Diet Study. *Diabet Med* **15**:290-6.
- 65:** Rhodes CJ. (2005) Type 2 diabetes—a matter of beta-cell life and death? *Science* **307**:380-4.
- 66:** Bonner-Weir S and Weir GC (2005). New sources of pancreatic beta-cells. *Nat Biotechnol* **23**:857-61.
- 67:** Marchetti P, Dotta F, Lauro D and Purrello F. (2008) An overview of pancreatic beta-cell defects in human type 2 diabetes: Implications for treatment. *Regul Pept.* **146**(1-3):4-11.
- 68:** Buchanan TA. (2003) Pancreatic beta-cell loss and preservation in type 2 diabetes. *Clin Ther* **25**(suppl B):32-46.
- 69:** Donath MY and Halban PA. (2004) Decreased beta-cell mass in diabetes: significance, mechanisms and therapeutic implications. *Diabetologia* **47**:581-9.
- 70:** Del Guerra S, Lupi R, Marselli L, et al. (2005) Functional and molecular alterations of pancreatic islets in human Type 2 diabetes. *Diabetes* **54**: 727-35.
- 71:** Butler AE, Janson J, Bonner-Weir S, et al. (2003) Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. *Diabetes* **52**: 102-10.
- 72:** Del Prato S, Marchetti P and Bonadonna RC. (2002) Phasic insulin release and metabolic regulation in type 2 diabetes. *Diabetes* **51**(suppl 1):S109-16.
- 73:** Marchetti P, Scharp DW, McLear M et al. (1994) Pulsatile insulin secretion from isolated human pancreatic islets. *Diabetes* **43**:827-30.
- 74:** Marchetti P, Del Prato S, Lupi R et al. (2006) The pancreatic beta-cell in human type 2 diabetes. *Nutr Metab Cardiovasc Dis* **16**(suppl 1):S3-6.
- 75:** Stumvoll M, Goldstein BJ and van Haeften TW. (2005) Type 2 diabetes: principles of pathogenesis and therapy. *Lancet* **365**:1333-46.
- 76:** Porksen N. (2002) The in vivo regulation of pulsatile insulin secretion. *Diabetologia* **45**:3-20.
- 77:** Schmitz O, Brock B, Hollingdal M, Juhl CB and Porksen N. (2002) High frequency insulin pulsatility and type 2 diabetes: from physiology and pathophysiology to clinical pharmacology. *Diabetes Metab* **28**(suppl 9):9-14.
- 78:** Lin JM, Febregat ME, Gomis R, et al. (2002) Pulsatile insulin release from islets isolated from three subjects with type 2 diabetes. *Diabetes* **51**: 988-93.

- 79:** Ahren B. (2004) Type 2 diabetes, insulin secretion and beta-cell mass. *Horm Metab Res* **36**:775–81.
- 80:** Roberts AN, Leighton B, Todd JA, Cockburn D, Schofield PN et al. (1989) Molecular and functional characterization of amylin, a peptide associated with type 2 diabetes mellitus. *Proc Natl Acad Sci U S A*. **86**(24):9662-6.
- 81:** Butler PC, Chou J, Carter WB, Wang YN, Bu BH et al. (1990) Effects of meal ingestion on plasma amylin concentration in NIDDM and nondiabetic humans. *Diabetes* **39**: 752–756.
- 82:** Hayden MR and Tyagi SC (2001) "A" is for amylin and amyloid in type 2 diabetes mellitus. *JOP*. **2**(4):124-39.
- 83:** Lukinius A, Korsgren O, Grimelius L and Wilander E. (1996) Expression of islet amyloid polypeptide in fetal and adult porcine and human pancreatic islet cells. *Endocrinology*. **137**(12): 5319-5325.
- 84:** D'Este L, Wimalawansa SJ and Renda TG. (1995) Amylin-immunoreactivity is co-stored in a serotonin cell subpopulation of the vertebrate stomach and duodenum. *Arch Histol Cytol*. **58**(5): 537-547.
- 85:** Brain SD, Williams TJ, Tippins JR, Morris HR and MacIntyre I. (1985) Calcitonin gene-related peptide is a potent vasodilator. *Nature*. **313**(5997):54-6.
- 86:** Cornish J, Callon KE, King AR, Cooper GJ and Reid IR. (1998) Systemic administration of amylin increases bone mass, linear growth, and adiposity in adult male mice. *Am J Physiol*. **275**(4 Pt 1):E694-9.
- 87:** Young A, Moore C, Herich J and Beaumont K. (1999) Neuroendocrine actions of amylin. *Austin, Tex: RG Landes Company*; **1999:91-102**.
- 88:** Gedulin BR, Rink TJ and Young AA. (1997) Dose-response for glucagonostatic effect of amylin in rats. *Metabolism*. **46**(1):67-70.
- 89:** Young AA, Gedulin B, Vine W, Percy A and Rink TJ. (1995) Gastric emptying is accelerated in diabetic BB rats and is slowed by subcutaneous injections of amylin. *Diabetologia*. **38**(6): 642-648.
- 90:** Rushing PA, Hagan MM, Seeley RJ, Lutz TA, D'Alessio DA, Air EL and Woods SC. (2001) Inhibition of central amylin signaling increases food intake and body adiposity in rats. *Endocrinology*. **142**(11):5035.
- 91:** Chapman I, Parker B, Doran S, Feinle-Bisset C, Wishart J et al. (2005) Effect of pramlintide on satiety and food intake in obese subjects and subjects with type 2 diabetes. *Diabetologia*. **48**(5):838-48.
- 92:** Buse J. B., Weyer C and Maggs DG. (2002) Amylin replacement with pramlintide in type 1 and type 2 diabetes: a physiological approach to overcome barriers with insulin therapy. *Clin Diabetes*. **220**:137-144.
- 93:** Leighton B and Cooper GJ. (1988) Pancreatic amylin and calcitonin gene-related peptide cause resistance to insulin in skeletal muscle in vitro. *Nature*. **335**(6191):632-5.
- 94:** Ostenson CG, Gaisano H, Sheu L, Tibell A and Bartfai T. (2006) Impaired gene and protein expression of exocytotic soluble N-ethylmaleimide attachment protein receptor complex proteins in pancreatic islets of type 2 diabetic patients. *Diabetes* **55**:435–40.
- 95:** Anello M, Lupi R, Spampinato D, et al. (2005) Functional and morphological alterations of mitochondria in pancreatic beta cells from type 2 diabetic patients. *Diabetologia* **48**:282–9.
- 96:** Welsh N, Cnop M, Kharroubi I, Bugiani M, Lupi R et al. (2005) Is there a role for locally produced interleukin-1 in the deleterious effects of high glucose or the type 2 diabetes mellitus to human pancreatic islets? *Diabetes* **54**:3238–44.

- 97:** Sladek R, Rocheleau G, Rung J, et al. (2007) A genome wide association study identifies novel risk loci for type 2 diabetes. *Nature* **445**:881–5.
- 98:** Bell GI and Polonski KS. (2001) Diabetes mellitus and genetically programmed defects in beta cell function. *Nature* **41**:788–91.
- 99:** Trajkovski M, Mziaut H, Schwarz PE and Solimena M. (2006) Genes of type 2 diabetes in beta cells. *Endocrinol Metab Clin North Am* **35**:357–69.
- 100:** Marchetti P, Lupi R, Federici M, et al. (2002) Insulin secretory function is impaired in isolated human islets carrying the gly972 arg IRS-1 polymorphism. *Diabetes* **51**:1419–24.
- 101:** Andreozzi F, D'Alessandris C, Federici M, et al. (2004) Activation of the hexosamine pathway leads to phosphorylation of IRS-1 on Ser307 and Ser612 and impairs the phosphatidylinositol 3-kinase/Akt/mTOR insulin biosynthetic pathway in RIN pancreatic beta-cells. *Endocrinology* **145**:2845–57.
- 102:** Lupi R, Dotta F, Marselli L, et al. (2002) Prolonged exposure to free fatty acids has cytostatic and pro-apoptotic effects on human pancreatic islets: evidence that beta-cell death is caspase mediated, partially dependent on ceramide pathway, and Bcl-2 regulated. *Diabetes* **51**:1437–42.
- 103:** Cnop M, Welsh N, Jonas JC, Jorns A, Lenzen S and Eizirik DL. (2005) Mechanisms of pancreatic beta-cell death in type 1 and type 2 diabetes: many differences, few similarities. *Diabetes* **54**(suppl 2):97–107.
- 104:** Prentki M and Nolan CJ. (2006) Islet beta cell failure in type 2 diabetes. *J Clin Invest* **116**:1802–12.
- 105:** Hoppener JWM and Lips CJM. (2006) Role of amyloid in type 2 diabetes mellitus. *Int J Biochem Cell Biol* **38**:726–36.
- 106:** Ritzel RA, Meier JJ, Lin CY, Veldhuis JD and Butler PC. (2007) Human islet amyloid polypeptide oligomers disrupt cell coupling, induce apoptosis, and impair insulin secretion in isolated human islets. *Diabetes* **56**:65–71.
- 107:** Hull RL, Westermark GT, Westermark P and Kahn SE. (2004) Islet amyloid: a critical entity in the pathogenesis of type 2 diabetes. *J Clin Endocrinol Metab*. **89**(8):3629–43.
- 108:** Kahn SE, Andrikopoulos S and Verchere CB. (1999) Islet amyloid: a long-recognized but underappreciated pathological feature of type 2 diabetes. *Diabetes*. **48**(2):241–53.
- 109:** Cooper GJ, Willis AC, Clark A, Turner RC, Sim RB and Reid KB. (1987) Purification and characterization of a peptide from amyloid-rich pancreases of type 2 diabetic patients. *Proc Natl Acad Sci U S A*. **84**(23):8628–32.
- 110:** Westermark P, Wernstedt C, O'Brien TD, Hayden DW and Johnson KH. (1987) Islet amyloid in type 2 human diabetes mellitus and adult diabetic cats contains a novel putative polypeptide hormone. *Am J Pathol*. **127**(3):414–7.
- 111:** Ritzel RA and Butler PC. (2003) Replication increases beta-cell vulnerability to human islet amyloid polypeptide-induced apoptosis. *J Clin Endocrinol Metab*. **88**(2):742–7.
- 112:** Hiddinga HJ and Eberhardt NL. (1999) Intracellular amyloidogenesis by human islet amyloid polypeptide induces apoptosis in COS-1 cells. *Am J Pathol*. **154**(4):1077–88.
- 113:** Westermark P, Engström U, Johnson KH, Westermark GT and Betsholtz C. (1990) Islet amyloid polypeptide: pinpointing amino acid residues linked to amyloid fibril formation. *Proc Natl Acad Sci U S A*. **87**(13):5036–40.
- 114:** Matveyenko AV and Butler PC. (2006) β -cell deficit due to increased apoptosis in the human Islet Amyloid Polypeptide Transgenic (HIP) rat recapitulates the metabolic defects present in Type 2 Diabetes. *Diabetes* **55**:2106–14.

- 115:** Höppener JW, Oosterwijk C, Nieuwenhuis MG, Posthuma G, Thijssen JH et al. (1999) Extensive islet amyloid formation is induced by development of Type II diabetes mellitus and contributes to its progression: pathogenesis of diabetes in a mouse model. *Diabetologia*. **42**(4): 427-34.
- 116:** Sakagashira S, Sanke T, Hanabusa T, Shimomura H, Ohagi S et al. (1996) Missense mutation of amylin gene (S20G) in Japanese NIDDM patients. *Diabetes*. **45**(9):1279-81.
- 117:** Jaikaran E and Clark A (2001) Islet amyloid and type 2 diabetes: from molecular misfolding to islet pathophysiology. *Biochim Biophys Acta*. **1537**(3):179-203.
- 118:** Marzban L, Trigo-Gonzalez G, Zhu X, Rhodes CJ, Halban PA et al. (2004) Role of beta-cell prohormone convertase (PC)1/3 in processing of pro-islet amyloid polypeptide. *Diabetes*. **53**(1): 141-8.
- 119:** Leckström A, Björklund K, Perment J, Larsson R and Westermark P. (1997) Renal elimination of islet amyloid polypeptide. *Biochem Biophys Res Commun*. **239**(1):265-8.
- 120:** Haataja L, Gurlo T, Huang CJ and Butler PC. (2008) Islet amyloid in type 2 diabetes, and the toxic oligomer hypothesis. *Endocr Rev*. **29**(3):303-16.
- 121:** Higham CE, Jaikaran ET, Fraser PE, Gross M and Clark A. (2000) Preparation of synthetic human islet amyloid polypeptide (IAPP) in a stable conformation to enable study of conversion to amyloid-like fibrils. *FEBS Lett*. **470**(1):55-60.
- 122:** Wei, L., Jiang, P., Yau, Y.H., Summer, H., Shochat, S.G., Mu, Y. and Pervushin, K. (2009) Residual structure in islet amyloid polypeptide mediates its interactions with soluble insulin. *Biochemistry* **48**, 2368–2376.
- 123:** Knight, J.D., Williamson, J.A. and Miranker, A.D. (2008). Interaction of membrane-bound islet amyloid polypeptide with soluble and crystalline insulin. *Protein Sci*. **17**,1850–1856.
- 124:** Engel MF. (2009) Membrane permeabilization by Islet Amyloid Polypeptide. *Chem Phys Lipids*. **160**(1):1-10.
- 125:** Kapurniotu A. (2001) Amyloidogenicity and cytotoxicity of islet amyloid polypeptide. *Biopolymers*. **60**(6):438-59.
- 126:** Khemtémourian L, Killian JA, Höppener JW and Engel MF. (2008) Recent insights in islet amyloid polypeptide-induced membrane disruption and its role in beta-cell death in type 2 diabetes mellitus. *Exp Diabetes Res*. **2008**:421287.
- 127:** Moriarty D. F. and Raleigh D. P. (1999) "Effects of sequential proline substitutions on amyloid formation by human amylin 20–29," *Biochemistry*, **38**(6):1811–1818.
- 128:** Azriel R. and. Gazit, E. (2001) "Analysis of the minimal amyloidforming fragment of the islet amyloid polypeptide—an experimental support for the key role of the phenylalanine residue in amyloid formation," *Journal of Biological Chemistry*. **276**(36):34156–34161.
- 129:** Marek P., Abedini A, Song, B et al. (2007) "Aromatic interactions are not required for amyloid fibril formation by islet amyloid polypeptide but do influence the rate of fibril formation and fibril morphology," *Biochemistry*, **46**(11):3255–3261.
- 130:** Abedini A and Raleigh D. P. (2005) "The role of His-18 in amyloid formation by human islet amyloid polypeptide," *Biochemistry*, **44**(49):16284–16291.
- 131:** Clark A. and. Nilsson M. R. (2004) "Islet amyloid: a complication of islet dysfunction or an aetiological factor in type 2 diabetes?" *Diabetologia*, **47**(2):157–169.
- 132:** Koo B. W and Miranker A. D. (2005) "Contribution of the intrinsic disulfide to the assembly mechanism of islet amyloid," *Protein Science*, **14**(1):231–239.
- 133:** Goldsbury C., Goldie K., Pellaud J., et al. (2000) "Amyloid fibril formation from full-length and fragments of amylin," *Journal of Structural Biology*, **130**(2-3):352–362.

- 134:** Knight J. D., Hebda J. A. and Miranker A. D. (2006) "Conserved and cooperative assembly of membrane-bound α -helical states of islet amyloid polypeptide," *Biochemistry*, **45**(31):9496–9508.
- 135:** Jayasinghe S. A. and Langen R. (2004) "Identifying structural features of fibrillar islet amyloid polypeptide using site-directed spin labeling," *Journal of Biological Chemistry*, **279**(46):48420–48425.
- 136:** Luca S, Yau WM, Leapman R and Tycko R. (2007) Peptide conformation and supramolecular organization in amylin fibrils: constraints from solid-state NMR. *Biochemistry*. **46**(47):13505-22.
- 137:** Kajava AV, Aebi U and Steven AC. (2005) The parallel superpleated beta-structure as a model for amyloid fibrils of human amylin. *J Mol Biol.* **348**(2):247-52.
- 138:** Kudva YC, Mueske C, Butler PC and Eberhardt NL. (1998) A novel assay in vitro of human islet amyloid polypeptide amyloidogenesis and effects of insulin secretory vesicle peptides on amyloid formation. *Biochem J* **331**:809–813.
- 139:** Harding HP, Zeng H, Zhang Y, Jungries R, Chung P et al. (2001) Diabetes mellitus and exocrine pancreatic dysfunction in perk-/- mice reveals a role for translational control in secretory cell survival. *Mol Cell* **7**:1153–1163.
- 140:** Hayden MR, Tyagi SC, Kerklo MM and Nicolls MR. (2005) Type 2 diabetes as a conformational disease. *JOP*. **6**(4):287-302.
- 141:** Marzban L, Park K and Verchere CB. (2003) Islet amyloid polypeptide and type 2 diabetes. *Experimental Gerontology* **38**:347–351
- 142:** Verchere C.B., D'Alessio, D.A., Palmiter, R.D., Weir, G.C., Bonner-Weir, S. et al. (1996) Islet amyloid formation associated with hyperglycemia in transgenic mice with pancreatic beta cell expression of human islet amyloid polypeptide. *Proc. Natl Acad. Sci. USA* **93**:3492–3496.
- 143:** Bennett RG, Hamel FG and Duckworth WC. (2003) An insulin-degrading enzyme inhibitor decreases amylin degradation, increases amylin-induced cytotoxicity, and increases amyloid formation in insulinoma cell cultures. *Diabetes* **52**:2315–2320.
- 144:** Abedini A, Tracz SM, Cho JH and Raleigh DP. (2006) Characterization of the heparin binding site in the N-terminus of human pro-islet amyloid polypeptide: implications for amyloid formation. *Biochemistry*. **45**(30):9228-37.
- 145:** Westermark P, Li ZC, Westermark GT, Leckström A and Steiner DF. (1996) Effects of beta cell granule components on human islet amyloid polypeptide fibril formation. *FEBS Lett.* **379**(3):203-6.
- 146:** Jha S, Sellin D, Seidel R and Winter R. (2009) Amyloidogenic propensities and conformational properties of ProAPP and IAPP in the presence of lipid bilayer membranes. *J Mol Biol.* **389**(5):907-20.
- 147:** Westermark GT, Steiner DF, Gebre-Medhin S, Engström U and Westermark P. (2000) Pro islet amyloid polypeptide (ProAPP) immunoreactivity in the islets of Langerhans. *Ups J Med Sci.* **105**(2):97-106.
- 148:** Park K and Verchere CB. (2001) Identification of a heparin binding domain in the N-terminal cleavage site of pro-islet amyloid polypeptide. Implications for islet amyloid formation. *J Biol Chem.* **276**(20):16611-6.
- 149:** Meng F, Abedini A, Song B and Raleigh DP. (2007) Amyloid formation by pro-islet amyloid polypeptide processing intermediates: examination of the role of protein heparan sulfate interactions and implications for islet amyloid formation in type 2 diabetes. *Biochemistry*. **46**(43):12091-9.

- 150:** Clark, A., Lewis, C.E., Willis, A.C., Cooper, G.J.S., Morris, J.F. et al. (1987). Islet amyloid formed from diabetes-associated peptide may be pathogenic in type-2 diabetes. *Lancet* **330**, 231–234.
- 151:** Lorenzo, A., Razzaboni, B., Weir, G.C. and Yankner, B.A., (1994) Pancreatic islet cell toxicity of amylin associated with type-2 diabetes mellitus. *Nature* **368**, 756–760.
- 152:** Westermark, P. (1973) Fine structure of islets of Langerhans in insular amyloidosis. *Virchows Arch. A Pathol. Pathol. Anat.* **359**, 1–18.
- 153:** Quist, A., Doudevski, I., Lin, H., Azimova, R., Ng, D., Frangione, B. et al. (2005) Amyloid ion channels: a common structural link for protein misfolding disease. *Proc. Natl. Acad. Sci. U.S.A.* **102**, 10427–10432.
- 154:** Kayed, R., Pensalfini, A., Margol, L., Sokolov, Y., Sarsoza, F. et al. (2009). Annular protofibrils are a structurally and functionally distinct type of amyloid oligomer. *J. Biol. Chem.* **284**, 4230–4237.
- 155:** Pellistri, F., Bucciantini, M., Relini, A., Nosi, D., Gliozzi, A. et al. (2008) Non-specific interaction of prefibrillar amyloid aggregates with NMDA and AMPA receptors results in Ca²⁺ increase in primary neuronal cells. *J. Biol. Chem.* **283**, 29950–29960.
- 156:** Kagan, B.L., Azimov, R. and Azimova, R. (2004). Amyloid peptide channels. *J. Membr. Biol.* **202**, 1–10.
- 157:** Engel, M.F.M., Khemtémourian, L., Kleijer, C.C., Meeldijk, H.J.D., Jacobs, J. et al. (2008) Membrane damage by human islet amyloid polypeptide through fibril growth at the membrane. *Proc. Natl. Acad. Sci. U.S.A.* **105**, 6033–6038.
- 158:** Domanov, Y.A and Kinnunen, P.K. (2008). Islet amyloid polypeptide forms rigid lipidprotein amyloid fibrils on supported phospholipid bilayers. *J. Mol. Biol.* **376**, 42–54.
- 159:** Gellermann, G.P., Appel, T.R., Tannert, A., Radestock, A., Hortschansky, P. et al. (2005) Raft lipids as common components of human extracellular amyloid fibrils. *Proc. Natl. Acad. Sci. U.S.A.* **102**, 6297–6302.
- 160:** Friedman, R., Pellarin, R. and Caflisch, A. (2009) Amyloid aggregation on lipid bilayers and its impact on membrane permeability. *J. Mol. Biol.* **387**, 407–415.
- 161:** Ren, P.H., Lauckner, J.E., Kachirskaia, I., Heuser, J.E., Melki, R and Kopito, R.R. (2009) Cytoplasmic penetration and persistent infection of mammalian cells by polyglutamine aggregates. *Nat. Cell Biol.* **11**, 219–225.
- 162:** Gonzalez, M.R., Bischofberger, M., Pernot, L., van der Goot, F.G and Freche, B. (2008) Bacterial pore-forming toxins: the (w)hole story? *Cell Mol. Life Sci.* **65**, 493–507.
- 163:** Konno, T., Oiki, S. and Morii, T. (2007) Synergistic action of polyanionic and non-polar cofactors in fibrillation of human islet amyloid polypeptide. *FEBS Lett.* **581**, 1635–1638.
- 164:** Ruschak, A.M. and Miranker, A.D. (2007) Fiber-dependent amyloid formation as catalysis of an existing reaction pathway. *Proc. Natl. Acad. Sci. U.S.A.* **104**, 12341–12346.
- 165:** Padrick, S.B. and Miranker, A.D. (2002) Islet amyloid: phase partitioning and secondary nucleation are central to the mechanism of fibrillogenesis. *Biochemistry* **41**, 4694–4703.
- 166:** Zhang, L., Zhong, J., Huang, L., Wang, L., Hong, Y. and Sha, Y. (2008) Parallel-oriented fibrogenesis of a -sheet forming peptide on supported lipid bilayers. *J. Phys. Chem. B* **112**, 8950–8954.
- 167:** Aisenbrey, C., Borowik, T., Byström, R., Bokvist, M., Lindström, F. et al. (2008) How is protein aggregation in amyloidogenic diseases modulated by biological membranes? *Eur. Biophys. J.* **37**, 247–255.
- 168:** Knight, J.D. and Miranker, A.D. (2004) Phospholipid catalysis of diabetic amyloid assembly. *J. Mol. Biol.* **341**, 1175–1187.

- 169:** Linse, S., Cabaleiro-Lago, C., Xue,W.F., Lynch, I., Lindman, S. et al. (2007) Nucleation of protein fibrillation by nanoparticles. *Proc.Natl. Acad. Sci. U.S.A.* **104**, 8691–8696.
- 170:** Griffin, M.D.W., Mok, M.L.Y., Wilson, L.M., Pham, C.L.L., Waddington, L.J. et al. (2008) Phospholipid interaction induces molecular level polymorphism in apolipoprotein C-II amyloid fibrils via alternative assembly pathways. *J. Mol. Biol.* **375**, 240–256.
- 171:** Zhang, S., Liu, J., Dragunow, M. and Cooper, G.J. (2003) Fibrillogenic amylin evokes islet-cell apoptosis through linked activation of a caspase cascade and JNK1. *J. Biol. Chem.* **278**, 52810–52819.
- 172:** Nanga, R.P., Brender, J.R., Xu, J., Veglia, G. and Ramamoorthy, A. (2008) Structures of rat and human islet amyloid polypeptide IAPP1–19 in micelles by NMR spectroscopy. *Biochemistry* **47**, 12689–12697.
- 173:** Engel, M.F.M., Yigittop, H., Elgersma, R.C., Rijkers, D.T.S., Liskamp, R.M.J. et al. (2006) Islet amyloid polypeptide inserts into phospholipid monolayers as monomer. *J. Mol. Biol.* **356**, 783–789.
- 174:** Apostolidou, M., Jayasinghe, S.A. and Langen R. (2008) Structure of -helical membranebound hIAPP and its implications for membrane-mediated misfolding. *J. Biol. Chem.* **283**, 17205–17210.
- 175:** Jayasinghe, S.A. and Langen, R. (2005) Lipid membranes modulate the structure of islet amyloid polypeptide. *Biochemistry* **44**, 12113–12119.
- 176:** Williamson, J.A. and Miranker, A.D. (2007) Direct detection of transient α -helical states in islet amyloid polypeptide. *Protein Sci.* **16**, 110–117.
- 177:** Williamson JA, Loria JP and Miranker AD. (2009) Helix stabilization precedes aqueous and bilayer-catalyzed fiber formation in islet amyloid polypeptide. *J Mol Biol.* **393**(2):383-96.
- 178:** Wajant H. (2002) The Fas signaling pathway: more than a paradigm. *Science* **296**:1635–1636.
- 179:** Finkel E. (2001) The mitochondrion: is it central to apoptosis? *Science* **292**:624–626.
- 180:** Marchetti P, Bugliani M, Lupi R, Marselli L, Masini M et al. (2007) The endoplasmic reticulum in pancreatic β -cells of type 2 diabetes patients. *Diabetologia* **50**:2486–2494.
- 181:** Huang CJ, Haataja L, Gurlo T, Butler AE, Wu X et al. (2007) Induction of endoplasmic reticulum stress-induced cell apoptosis and accumulation of polyubiquitinated proteins by human islet amyloid polypeptide. *Am J Physiol Endocrinol Metab* **293**:E1656–E1662.
- 182:** Huang CJ, Gurlo T, Haataja L, Costes S, Daval M. et al. (2010) Calcium-activated calpain-2 is a mediator of beta cell dysfunction and apoptosis in type 2 diabetes. *J Biol Chem.* **285**(1):339-48.
- 183:** Wootz H, Hansson I, Korhonen L, Napankangas U and Lindholm D. (2004) Caspase-12 cleavage and increased oxidative stress during motoneuron degeneration in transgenic mouse model of ALS. *Biochem Biophys Res Commun* **322**:281–286.
- 184:** Katayama T, Imaizumi K, Manabe T, Hitomi J, Kudo T and Tohyama M. (2004) Induction of neuronal death by ER stress in Alzheimer's disease. *J Chem Neuroanat* **28**:67–78.
- 185:** Oyadomari S, Koizumi A, Takeda K, Gotoh T, Akira S. et al. (2002) Targeted disruption of the Chop gene delays endoplasmic reticulum stress mediated diabetes. *J Clin Invest* **109**:525-32.
- 186:** Butler PC. (2004) Apoptosis and the beta-cell in type 1 and type 2 diabetes. *Horm Res* **62**(Suppl 3):66.
- 187:** Jones LC and Clark A. (2001) beta-cell neogenesis in type 2 diabetes. *Diabetes* **50**:S186-7.

- 188:** Waterman E and Lockwood B. (2007) Active components and clinical applications of olive oil. *Altern Med Rev.* **12**(4):331-42.
- 189:** Tripoli E, Giannanco M, Tabacchi G, Di Majo D, Giannanco S and La Guardia M. (2005) The phenolic compounds of olive oil: structure, biological activity and beneficial effects on human health. *Nutr Res Rev.* **18**(1):98-112.
- 190:** Newmark HL. (1997) Squalene, olive oil, and cancer risk: a review and hypothesis. *Cancer Epidemiol Biomarkers Prev* **6**:1101-1103.
- 191:** Vissioli F, Bellomo G and Galli C. (1998) Free Radical-Scavenging Properties of Olive Oil Polyphenols. *Biochem and Biophys Res. Comm.* **247**,60-64.
- 192:** Covas MI. (2008) Bioactive effects of olive oil phenolic compounds in humans: reduction of heart disease factors and oxidative damage. *Inflammopharmacology* **16**: 216–218.
- 193:** Servili M, Esposto S, Fabiani R, Urbani S, Taticchi A. et al. (2009) Phenolic compounds in olive oil: antioxidant, health and organoleptic activities according to their chemical structure. *Inflammopharmacology* **17**:76–84.
- 194:** Tuck KL and Hayball PJ (2002) Major phenolic compounds in olive oil: metabolism and health effects. *Journal of Nutritional Biochemistry* **13**, 636–644.
- 195:** Owen RW, Mier W, Giacosa A, et al. (2000) Phenolic compounds and squalene in olive oils: the concentration and antioxidant potential of total phenols, simple phenols, secoiridoids, lignans and squalene. *Food Chem Toxicol* **38**:647-659.
- 196:** Vissioli F, Poli A and Galli C (2002) Antioxidant and other biological activities of phenols from olives and olive oil. *Medicinal Research Reviews* **22**, 65–75.
- 197:** Rovellini, P., Cortesi, N. and Fedeli E. (1997) Analysis of flavonoids from Olea europaea by HPLC–UV and HPLC–Electrospray–MS, *Riv. Ital. Sostanze Grasse*, **74**, 273–9.
- 198:** Montedoro, G. F., Servili, M., Baldioli, M. et al. (1992) Simple and hydrolyzable phenolic compounds in virgin olive oil. 2. Initial characterization of the hydrolyzable fraction, *J. Agric. Food Chem.* **40**, 1571–6.
- 199:** Montedoro, G. F., Servili, M. Baldioli, M. et al. (2002) The Use of biotechnology means during oil mechanical extraction process: relationship with sensory and nutritional parameters of virgin olive oil quality, *Acta Horticult.* **586**, 557–60.
- 200:** Fleming HP, Walter JRnand Etchells JL. (1973) Antimicrobial Properties of Oleuropein and Products of Its Hydrolysis from Green Olives. *Applied micro.* **26**(5), p. 777-782.
- 201:** Leene R, Roodenburg A, Vissers M, Schuurbiers J, Van Putte K et al. (2002) Supplementation of Plasma with Olive Oil Phenols and Extracts: Influence on LDL Oxidation. *J. Agric. Food Chem.* **50**, 1290-1297.
- 202:** Jemai H, Bouaziz M, Fki I, El Feki A and Sayadi S. (2008) Hypolipidemic and antioxidant activities of oleuropein and its hydrolysis derivative-rich extracts from Chemlali olive leaves. *Chem Biol Interact.* **176**(2-3):88-98.
- 203:** Dell'Agli M, Maschi O, Galli GV, Fagnani R, Dal Cero E. et al. (2008) Inhibition of platelet aggregation by olive oil phenols via cAMP-phosphodiesterase. *Br J Nutr.* **99**(5):945-51.
- 204:** Dell'Agli M, Fagnani R, Mitro N, Scurati S, Masciadri M. et al. (2006) Minor components of olive oil modulate proatherogenic adhesion molecules involved in endothelial activation. *J Agric Food Chem.* **54**(9):3259-64.
- 205:** Vissioli F, Bellostta S, and Galli C. (1998) Oleuropein, the bitter principle of olives, enhances nitric oxide production by mouse macrophages. *Life Sciences*, **62**(6):5.41~546.
- 206:** Fabiani R, Rosignoli P, De Bartolomeo A, Fuccelli R, Servili M, Montedoro GF and Morozzi G. (2008) Oxidative DNA damage is prevented by extracts of olive oil, hydroxytyrosol, and other

- olive phenolic compounds in human blood mononuclear cells and HL60 cells. *J Nutr.* **138**(8): 1411-6.
- 207:** Corona G, Deiana M, Incani A, Vauzour D, Dessì MA and Spencer JP. (2007) Inhibition of p38/CREB phosphorylation and COX-2 expression by olive oil polyphenols underlies their anti-proliferative effects. *Biochem Biophys Res Commun.* **362**(3):606-11.
- 208:** Procopio A, Alcaro S, Nardi M, Oliverio M, Ortuso F et al. (2009) Synthesis, Biological Evaluation, and Molecular Modeling of Oleuropein and Its Semisynthetic Derivatives as Cyclooxygenase Inhibitors. *J. Agric. Food Chem.* **57**(23):11161-7.
- 211:** Menendez JA, Vazquez-Martin A, Colomer R, Brunet J, Carrasco-Pancorbo A. et al. (2007) Olive oil's bitter principle reverses acquired autoresistance to trastuzumab (Herceptin) in HER2-overexpressing breast cancer cells. *BMC Cancer.* **7**:80.
- 212:** Vissers MN, Zock PL, Roodenburg AJC, Leenen R and Katan MB. (2002) Olive oil phenols are adsorbed in humans. *J Nutr* **132**:409–17.
- 213:** Porat Y, Abramowitz A and Gazit E. (2006) Inhibition of amyloid fibril formation by polyphenols: structural similarity and aromatic interactions as a common inhibition mechanism. *Chem Biol Drug Des* **67**:27–37.
- 214:** Meier JJ, Kayed R, Lin CY, Gurlo T, Haataja L, Jayasinghe SJ, et al. (2006) Inhibition of human IAPP fibril formation does not prevent β -cell death: evidence for distinct actions of oligomers and fibrils of human IAPP. *Am J Physiol Endocrinol Metab* **291**:1317–24.
- 215:** Porat Y, Mazor Y, Efrat S and Gazit E. (2004) Inhibition of islet amyloid polypeptide fibril formation: a potential role for heteroaromatic interactions. *Biochemistry* **43**:14454–62.
- 216:** Ritzel RA and Butler PC. (2003) Replication increases beta-cell vulnerability to human islet amyloid polypeptide-induced apoptosis. *Diabetes* **52**:1701–8.
- 217:** Yan LM, Tatarek-Nossol M, Velkova A, Kazantzis A and Kapurniotu A. (2006) Design of a mimic of nonamyloidogenic and bioactive human islet amyloid polypeptide (IAPP) as nanomolar affinity inhibitor of IAPP cytotoxic fibrillogenesis. *Proc Natl Acad Sci U S A* **103**:2046–51.
- 218:** Konno K, Hirayama C, Yasui H and Nakamura M. (1999) Enzymatic activation of oleuropein: a protein crosslinker used as chemical defence by privet tree. *Proc Natl Acad Sci USA* **96**:9159–62.
- 219:** Abe K and Kimura H. (1996) Amyloid beta toxicity consists of a Ca(2+)-independent early phase and a Ca(2+)-dependent late phase. *J Neurochem.* **67**(5):2074-8.
- 220:** Liu Y, Peterson DA, Kimura H and Schubert D. (1997) Mechanism of cellular 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) reduction. *J Neurochem.* **69**(2): 581-93.
- 221:** Kayed R, Bernhagen J, Greenfield N, Sweimeh KM, Brunner H. et al. (1999) Conformational transitions of islet amyloid polypeptide (IAPP) in amyloid formation in vitro. *J Mol Biol* **287**:781–96.
- 222:** Engel MFM, Khemtémourian L, Kleijer CC, Meeldijk HJD, Jacobs J. et al. (2008) Membrane damage by human islet amyloid polypeptide through fibril growth at the membrane. *Proc Natl Acad Sci U S A* **105**:6033–48.
- 223:** LeVine III H. (1999) Quantification of beta-sheet amyloid fibril structures with Thioflavine T. *Methods Enzymol* **309**:274–84.
- 224:** Rigacci S, Guidotti V, Bucciantini M, Parri M, Nediani C, Cerbai E, Stefani M, Berti A. (2009) Oleuropein aglycon prevents cytotoxic amyloid aggregation of human amylin. *J Nutr Biochem.* [Epub ahead of print]

- 225:** Wyttenbach A, Sauvageot O, Carmichael J, Diaz-Latoud C, Arrigo AP. and Rubinsztein DC. (2002) Heat shock protein 27 prevents cellular polyglutamine toxicity and suppresses the increase of reactive oxygen species caused by huntingtin. *Hum Mol Genet.* **11**(9):1137-51.
- 226:** Junn E. and Mouradian MM. (2002) Human alpha-synuclein over-expression increases intracellular reactive oxygen species levels and susceptibility to dopamine. *Neurosci Lett.* **320**(3):146-50.
- 227:** Lee G, Pollard HB and Arispe N. (2002) Annexin 5 and apolipoprotein E2 protect against Alzheimer's amyloid-beta-peptide cytotoxicity by competitive inhibition at a common phosphatidylserine interaction site. *Peptides* **23**(7):1249-63.
- 228:** Cerdà-Costa N, Esteras-Chopo A, Aviles FX, Serrano L, Villegas V. (2007) Early kinetics of amyloid fibril formation reveals conformational reorganisation of initial aggregates. *J Mol Biol* **366**:1351–3.
- 229:** Rigacci S, Bucciantini M, Relini A, Pesce A, Glioza A. et al. (2008) The (1-63) region of the p53 transactivation domain aggregates in vitro into cytotoxic amyloid assemblies. *Biophys J* **94**:3635–46.
- 230:** Mishra R, Sellin D, Radovan D, Gohlke A and Winter R. (2009) Inhibiting islet amyloid polypeptide fibril formation by the red wine compound resveratrol. *Chembiochem* **10**:445–9.
- 231:** Tracz SM, Abedini A, Driscoll M. and Raleigh DP. (2004) Role of aromatic interactions in amyloid formation by peptides derived from human amylin. *Biochemistry* **43**:15901–8.
- 232:** Bazoti FN, Bergquist J, Markides KE. and Tsarbopoulos A. (2006) Noncovalent interaction between amyloid- β -peptide (1-40) and oleuropein studied by electrospray ionization mass spectrometry. *J Am Soc Mass Spectrom* **17**:568–75.
- 233:** Bazoti FN, Bergquist J, Markides K. and Tsarbopoulos A. (2008) Localization of the noncovalent binding site between amyloid- β -peptide and oleuropein using electrospray ionization FT-ICR mass spectrometry. *J Am Soc Mass Spectrom* **19**:1078–85.
- 234:** Corona G, Tzounis X, Dessì MA, Deiana M, Debnam ES. et al. (2006) The fate of olive oil polyphenols in the gastrointestinal tract: implications of gastric and colonic microflora-dependent biotransformation. *Free Radic Res* **40**:647–58.